ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Impact of the COVID-19 pandemic on anticoagulation control for patients using warfarin

L. O'Loughlin1, S. Shah2, C. Hubbard2, G. Barnes3, M. Fang2, D. Kazi4, R. Patell4

1Beth Israel Deaconess Medical Center, Brookline, Massachusetts, United States, 2University of California San Francisco, San Francisco, California, United States, 3University of Michigan, Ann Arbor, Michigan, United States, 4Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Abstract Number: PB0081

Meeting: ISTH 2022 Congress

Theme: COVID and Coagulation » COVID and Coagulation, Clinical

Background: Patients on warfarin require regular international normalized ratio (INR) monitoring. The SARS-CoV-2 pandemic may have substantially affected in-person medical visits and laboratory testing. However, it is not clear how warfarin monitoring practices have been affected by the pandemic, given the importance of tight INR control.

Aims: To assess whether chronic warfarin management, as measured by INR testing frequency and time in therapeutic range (TTR), differed during the COVID-19 pandemic compared with the pre-pandemic period.

Methods: We identified all patients enrolled in an anticoagulation clinic associated with an urban academic medical between January 1, 2019 and May 31, 2021 with at least 2 INRs checked during this time period. We calculated frequency of INRs checked per month and TTR based on individual INR goals and compared the pre-pandemic (Jan 2019-Feb 2020) and pandemic (March 2020-May 2021) periods. INR frequency and TTR were modeled as a function of time period using Poisson and linear regressions respectively, accounting for repeated observations.

Results: Of the 1052 patients included, 43.9% were women and average age was 66.3 years. Pre-pandemic, an average of 1.58 (95% CI 1.52-1.64) INRs were checked per month, as compared with 1.09 (95% CI 1.03-1.15) in the pandemic period (p < 0.001) (Figure 1). Average TTR per month was also calculated (Figure 2). On average, TTR was 56.8% (95% CI 54.9-58.8%) pre-pandemic compared to 39.4% (95% CI 37.5-41.5%) during the pandemic period (p < 0.001).

Conclusion(s): There was a significant decrease in the frequency of INR measurements as well as TTR during the pandemic. A number of factors may have contributed to this, including regulatory and logistical constraints on clinic and laboratory visits and patient anxiety about visiting medical facilities. Larger scale studies are warranted to further characterize pandemic effects on warfarin use and monitoring, as well as clinically significant outcomes of thrombosis and hemorrhage.

Image

Figure 1: Average INR frequency plotted by month from 1/1/19 to 5/31/21. Dashed horizontal line represents three-month moving average. Dashed vertical line at March 2020 represents the end of the “pre-pandemic” period and beginning of the “pandemic” period.

Image

Figure 2: Average time in therapeutic range -TTR- plotted by month from 1/1/19 to 5/31/21. Dashed vertical line at March 2020 represents the end of the “pre-pandemic” period and beginning of the “pandemic” period.

To cite this abstract in AMA style:

O'Loughlin L, Shah S, Hubbard C, Barnes G, Fang M, Kazi D, Patell R. Impact of the COVID-19 pandemic on anticoagulation control for patients using warfarin [abstract]. https://abstracts.isth.org/abstract/impact-of-the-covid-19-pandemic-on-anticoagulation-control-for-patients-using-warfarin/. Accessed September 27, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/impact-of-the-covid-19-pandemic-on-anticoagulation-control-for-patients-using-warfarin/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress ยป

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley